Biobeat vs Etiometry (2026)
Both put physiologic data to work in hospitals, from different sources. Biobeat makes wearable monitors, a single use chest patch and a wrist device, that derive blood pressure without a cuff, oxygen saturation, pulse and more from an optical sensor, feeding a cloud platform for hospital wards, long term care and home programs. The measurements are FDA cleared; the AI early warning score it markets on top of them sits outside every clearance. Etiometry aggregates ICU data across device vendors and runs physiologic risk indices that estimate whether a patient is in a defined physiologic state now. Its FAQ claims adult clearance for all four indices; the current clearance covers three, for children up to 12. Choose Biobeat to add continuous monitoring where patients are not wired up; choose Etiometry to interpret data already flowing in critical care.
- Patients on wards or at home are not continuously monitored today.
- You want cuffless blood pressure and oxygen saturation from a wearable.
- One platform should cover hospital, long term care and home programs.
- Your ICU needs data aggregated across device vendors.
- You want estimates of a patient's current physiologic state.
- Your patients are children in critical care, within the cleared indication.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Biobeat and Etiometry are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Biobeat | Etiometry |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Inpatient Deterioration & Risk Monitoring |
| Founded | 2016 | Not recorded |
| Headquarters | Petah Tikva, Israel | Dedham, Massachusetts, United States |
| Website | bio-beat.com | etiometry.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Biobeat sells wearable vital sign monitors and a cloud platform for hospitals, long term care and home programs. The hardware is a single use chest patch and a wrist worn device built on a reflective photoplethysmography sensor, and from that optical signal the company derives blood pressure without a cuff (after calibration against a cleared cuff), oxygen saturation, pulse rate, respiratory rate, body temperature, stroke volume and cardiac output.
Source: AI Health Index, September 2026
Etiometry, based in Dedham, Massachusetts, sells a clinical intelligence platform for critical care that combines vendor neutral ICU data aggregation with four FDA cleared physiologic risk indices. The indices do not predict a coded outcome; each estimates the probability that a patient is currently in a defined physiologic state, specified against a laboratory threshold.
Source: AI Health Index, September 2026
Questions buyers ask
How are Biobeat and Etiometry priced and sold?
For Biobeat, the chest patch is single use and runs for up to 120 hours per the clearance summary, so cost recurs with every monitored patient and scales with how widely a ward deploys it, alongside the wrist device and the cloud platform; the company also offers ambulatory blood pressure monitoring and home sleep services.
With Etiometry, the platform is licensed to hospitals and installed on hospital virtual servers, with a described implementation (technical readiness, super user and unit training, ongoing clinical meetings) that can take about two months; device data may arrive through integration platforms the hospital licenses separately. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Biobeat and Etiometry handle patient data?
In Biobeat's case, the in hospital monitoring page describes a secure, HIPAA and GDPR compliant cloud based patient management system, and the clearance summaries describe the path: patch to a Bluetooth gateway to the cloud to a web application.
For Etiometry, the platform runs inside the hospital's environment, which limits exposure for identified data. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do Biobeat and Etiometry cover?
With Biobeat, the company offers a hospital solution for short term monitoring, a telehealth solution for long term monitoring, and at home services including ambulatory blood pressure monitoring and a home sleep lab, and has described use across wards, step down and post surgical units, long term care and hospital at home.
In Etiometry's case, the cleared indications (K254066) confine three of the four indices to children 0 to 12 years in intensive care and allow IDO2 in adults only in intensive care and off mechanical circulatory support; the data aggregation module is cleared for adult, pediatric and neonatal patients. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Biobeat and Etiometry?
For Biobeat, the study is single program and company led, and no named hospital deployment reports results.
With Etiometry, the home page leads with "Reduce Length of Stay by up to 36%" and readmissions "by up to 41%". The 36 percent traces to a 2017 conference abstract (Salvin, Circulation supplement). From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Inpatient Deterioration & Risk Monitoring page.
Both records were reviewed on this site in September 2026. Neither publishes a price. Biobeat's early warning score and alerts carry no clearance and no stated regulatory position, and Etiometry's marketing claims more clearance than it holds.
Ask both to show which of their outputs FDA has cleared, and for which patients.